Equities analysts forecast that Bruker Co. (NASDAQ:BRKR) will post $507.49 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Bruker’s earnings, with the highest sales estimate coming in at $509.00 million and the lowest estimate coming in at $504.60 million. Bruker reported sales of $470.30 million during the same quarter last year, which would suggest a positive year over year growth rate of 7.9%. The business is expected to issue its next quarterly earnings results after the market closes on Thursday, February 8th.
On average, analysts expect that Bruker will report full year sales of $507.49 million for the current fiscal year, with estimates ranging from $1.74 billion to $1.75 billion. For the next year, analysts anticipate that the business will report sales of $1.82 billion per share, with estimates ranging from $1.78 billion to $1.84 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Bruker.
Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. The business had revenue of $435.60 million during the quarter, compared to analysts’ expectations of $415.45 million. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.32 earnings per share.
A number of brokerages have recently commented on BRKR. BidaskClub cut shares of Bruker from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 11th. BTIG Research began coverage on shares of Bruker in a research report on Friday, January 5th. They issued a “buy” rating and a $42.00 target price for the company. Zacks Investment Research upgraded shares of Bruker from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a research report on Thursday, January 4th. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 target price on shares of Bruker in a research report on Thursday, December 14th. Finally, Evercore ISI began coverage on shares of Bruker in a research report on Wednesday, January 3rd. They set an “in-line” rating and a $36.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $32.38.
Shares of Bruker (NASDAQ:BRKR) traded down $0.32 during midday trading on Friday, hitting $35.33. 569,344 shares of the stock were exchanged, compared to its average volume of 508,541. The firm has a market capitalization of $5,510.00, a PE ratio of 37.59, a price-to-earnings-growth ratio of 2.63 and a beta of 1.12. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60. Bruker has a 1-year low of $21.83 and a 1-year high of $36.53.
A number of institutional investors have recently added to or reduced their stakes in BRKR. Legal & General Group Plc increased its position in Bruker by 10.7% during the second quarter. Legal & General Group Plc now owns 38,646 shares of the medical research company’s stock worth $1,114,000 after purchasing an additional 3,741 shares during the last quarter. Teachers Advisors LLC boosted its stake in Bruker by 65.8% during the second quarter. Teachers Advisors LLC now owns 245,720 shares of the medical research company’s stock worth $7,087,000 after buying an additional 97,491 shares during the period. TIAA CREF Investment Management LLC boosted its stake in Bruker by 19.4% during the second quarter. TIAA CREF Investment Management LLC now owns 478,258 shares of the medical research company’s stock worth $13,793,000 after buying an additional 77,603 shares during the period. Ameriprise Financial Inc. boosted its stake in Bruker by 296.7% during the second quarter. Ameriprise Financial Inc. now owns 98,231 shares of the medical research company’s stock worth $2,833,000 after buying an additional 73,469 shares during the period. Finally, BlackRock Inc. boosted its stake in Bruker by 3.0% during the second quarter. BlackRock Inc. now owns 4,747,514 shares of the medical research company’s stock worth $136,918,000 after buying an additional 139,792 shares during the period. Hedge funds and other institutional investors own 65.77% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “$507.49 Million in Sales Expected for Bruker Co. (BRKR) This Quarter” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/14/507-49-million-in-sales-expected-for-bruker-co-brkr-this-quarter.html.
Bruker Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Get a free copy of the Zacks research report on Bruker (BRKR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.